<DOC>
	<DOCNO>NCT00102804</DOCNO>
	<brief_summary>This study randomize Phase 3 , double-blind study maintenance pemetrexed plus best supportive care versus placebo plus best supportive care NSCLC . Participants must receive 1 6 induction regimens 4 cycle progressive disease prior randomization ( enrollment ) trial .</brief_summary>
	<brief_title>Pemetrexed Best Supportive Care Versus Placebo Best Supportive Care Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis NSCLC Stage IIIB ( pleural effusion and/or positive supraclavicular lymph node ) Stage IV prior induction therapy . Participants must 1 follow induction therapy treatment Stage IIIB ( pleural effusion and/or positive supraclavicular lymph node ) IV NSCLC : Gemcitabine plus carboplatin , paclitaxel plus carboplatin , docetaxel plus carboplatin , gemcitabine plus cisplatin , paclitaxel plus cisplatin docetaxel plus cisplatin . Participants must receive 1 chemotherapeutic doublet last precisely 4 cycle . Induction regimens must base 21day cycle . Documented evidence tumor response complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) . Tumor assessment must occur Cycle 4 ( Day 1 ) induction therapy date randomization . This response confirm order participant randomize . Positron emission tomography ( PET ) scan ultrasounds may use lesion measurement response determination . With exception chemotherapy list inclusion criterion , participant include receive prior systemic anticancer therapy ( include adjuvant earlystage treatment NSCLC ) systemic treatment cancer . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Inability comply protocol study procedure . A serious concomitant systemic disorder would compromise participant 's ability complete study . A serious cardiac condition , myocardial infarction within 6 month , angina , heart disease , define New York Heart Association Class III IV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>